BR0313197A - Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico - Google Patents
Agentes citotóxicos contendo potentes taxanos e seu uso terapêuticoInfo
- Publication number
- BR0313197A BR0313197A BR0313197-1A BR0313197A BR0313197A BR 0313197 A BR0313197 A BR 0313197A BR 0313197 A BR0313197 A BR 0313197A BR 0313197 A BR0313197 A BR 0313197A
- Authority
- BR
- Brazil
- Prior art keywords
- taxanes
- cell
- cytotoxic
- therapeutic use
- binding agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
"AGENTES CITOTóXICOS CONTENDO POTENTES TAXANOS E SEU USO TERAPêUTICO". A presente invenção refere-se a taxanos potentes contendo um grupo de ligação. Também está incluído um agente citotóxico compreendendo um ou mais taxanos ligados a um agente de ligação de célula. Uma composição terapêutica para induzir a morte de células em populações de células selecionadas compreendendo: (A) uma quantidade citotóxica de um ou mais taxanos covalentemente ligados a um agente de ligação de célula através de um grupo de ligação, e (B) um veículo diluente ou excipiente farmaceuticamente aceitável também está incluído. Um método para induzir morte de células em populações de células selecionadas compreendendo contatar células alvo ou tecido contendo células alvo com uma quantidade eficaz de um agente citotóxico compreendendo um ou mais taxanos ligados a um agente de ligação de célula também está incluído.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21011202A | 2002-08-02 | 2002-08-02 | |
US10/369,563 US7390898B2 (en) | 2002-08-02 | 2003-02-21 | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
PCT/US2003/019558 WO2004013093A2 (en) | 2002-08-02 | 2003-07-14 | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313197A true BR0313197A (pt) | 2005-08-09 |
Family
ID=31498026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313197-1A BR0313197A (pt) | 2002-08-02 | 2003-07-14 | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico |
Country Status (12)
Country | Link |
---|---|
US (2) | US7495114B2 (pt) |
EP (1) | EP1534674A4 (pt) |
JP (1) | JP2005539009A (pt) |
KR (1) | KR20050032110A (pt) |
CN (1) | CN100522955C (pt) |
AU (1) | AU2003247587B2 (pt) |
BR (1) | BR0313197A (pt) |
CA (1) | CA2494074A1 (pt) |
IL (1) | IL166624A0 (pt) |
MX (1) | MXPA05001390A (pt) |
NO (1) | NO20051108L (pt) |
WO (1) | WO2004013093A2 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
JP2008504216A (ja) * | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
EP1768963A4 (en) * | 2004-06-03 | 2009-06-10 | Smithkline Beecham Cork Ltd | CANCER TREATMENT METHOD |
EP1688415A1 (en) * | 2004-12-07 | 2006-08-09 | Aventis Pharma S.A. | Cytotoxic agents comprising new C-2 modified taxanes |
EP1669358A1 (en) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
CA2616906A1 (en) * | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
JP5622390B2 (ja) | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
CN104043123B (zh) * | 2007-01-25 | 2019-08-13 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
AU2008227123B2 (en) * | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
KR20100123674A (ko) * | 2007-09-21 | 2010-11-24 | 싸이티뮨 사이언스, 인크. | 나노치료제 콜로이드성 금속 조성물 및 방법 |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
WO2009062138A1 (en) * | 2007-11-08 | 2009-05-14 | Virginia Tech Intellectual Properties, Inc. | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents |
EP3100745B1 (en) | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EP2531173B1 (en) * | 2010-02-03 | 2018-09-26 | Oncbiomune, L.L.C. | Taxane- and taxoid-protein compositions |
RU2573994C2 (ru) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Антитела против cd20 и их применение |
KR20140010067A (ko) | 2011-02-15 | 2014-01-23 | 이뮤노젠 아이엔씨 | 컨쥬게이트의 제조방법 |
SG195172A1 (en) | 2011-06-21 | 2013-12-30 | Immunogen Inc | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
CN105121419B (zh) * | 2013-12-24 | 2016-08-03 | 于跃 | Cabazitaxel类抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法 |
US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
JP6606545B2 (ja) | 2014-09-03 | 2019-11-13 | イミュノジェン・インコーポレーテッド | 細胞障害性ベンゾジアゼピン誘導体 |
WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
SG11201704487XA (en) | 2014-12-04 | 2017-06-29 | Celgene Corp | Biomolecule conjugates |
CN107708810B (zh) | 2015-06-29 | 2021-10-22 | 伊缪诺金公司 | 半胱氨酸工程化抗体的结合物 |
CN108026103B (zh) | 2015-07-21 | 2021-04-16 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂䓬衍生物的方法 |
FI3380525T3 (fi) | 2015-11-25 | 2024-01-30 | Immunogen Inc | Lääkeformulaatioita ja niiden käyttömenetelmiä |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
AU2017363237B2 (en) | 2016-11-23 | 2022-03-17 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
RU2765098C2 (ru) | 2017-02-28 | 2022-01-25 | Иммуноджен, Инк. | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты |
WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019133652A1 (en) | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Benzodiazepine derivatives |
MX2021011330A (es) | 2019-03-20 | 2021-12-10 | Univ California | Anticuerpos de claudina-6 y conjugados de fármacos. |
US20230094471A1 (en) | 2019-03-29 | 2023-03-30 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
DK3958977T3 (en) | 2019-04-26 | 2023-12-11 | Immunogen Inc | Camptothecinderivater |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
TW202146055A (zh) | 2020-02-25 | 2021-12-16 | 美商麥迪波士頓股份有限公司 | 喜樹鹼衍生物及其結合物 |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
US20240108744A1 (en) | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6028205A (en) | 1991-09-23 | 2000-02-22 | Florida State University | C2 tricyclic taxanes |
US5728725A (en) | 1991-09-23 | 1998-03-17 | Florida State University | C2 taxane derivaties and pharmaceutical compositions containing them |
US5399726A (en) | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
US5356928A (en) * | 1992-11-06 | 1994-10-18 | Hauser Chemical Research, Inc. | Cytotoxic agents |
US5646176A (en) * | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
IL108443A0 (en) * | 1993-01-29 | 1994-04-12 | Univ Florida State | C7 taxane derivatives and pharmaceutical compositions containing them |
US6339164B1 (en) | 1993-01-29 | 2002-01-15 | Florida State University | C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them |
US5703247A (en) * | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
CA2129288C (en) * | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
WO1996011683A1 (en) * | 1994-10-14 | 1996-04-25 | Hauser Chemical Research, Inc. | New cytotoxic agents |
AU4548296A (en) * | 1995-02-02 | 1996-08-21 | Daiichi Pharmaceutical Co., Ltd. | Ether derivative |
CN1211919A (zh) * | 1995-09-13 | 1999-03-24 | 佛罗里达州立大学 | 放射增敏性紫杉烷及其药物制剂 |
CA2255615C (en) | 1996-05-22 | 2006-08-29 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel |
JP2001505194A (ja) | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
US5811452A (en) | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
CA2305399A1 (en) * | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Taxoid derivatives and process for producing the same |
US6545125B1 (en) | 1997-11-18 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP4808846B2 (ja) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | 癌の標的付けられた治療のためのタキサン誘導体 |
DK1242401T3 (da) | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf |
US6175023B1 (en) | 2000-01-31 | 2001-01-16 | Jian Liu | Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III |
NZ514406A (en) * | 2000-02-02 | 2005-01-28 | Univ Florida State Res Found | C10 heterosubstituted acetate taxanes as antitumor agents |
WO2001057030A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | C7 carbonate substituted taxanes as antitumor agents |
CZ20013519A3 (cs) * | 2000-02-02 | 2002-04-17 | Florida State University Research Foundation, Inc. | Taxany s C7 heterosubstituovaným acetátem jako protinádorové látky |
BR0104358A (pt) * | 2000-02-02 | 2002-01-02 | Univ Florida State Res Found | Formulações de taxana tendo solubilidade aperfeiçoada |
DE60133600T2 (de) * | 2000-02-02 | 2009-06-10 | Florida State University Research Foundation, Inc., Tallahassee | C7-carbamoyloxysubstituierte taxane als antitumormittel |
US6596757B1 (en) * | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
-
2003
- 2003-07-14 AU AU2003247587A patent/AU2003247587B2/en not_active Ceased
- 2003-07-14 EP EP03766820A patent/EP1534674A4/en not_active Withdrawn
- 2003-07-14 CN CNB038232480A patent/CN100522955C/zh not_active Expired - Fee Related
- 2003-07-14 KR KR1020057001946A patent/KR20050032110A/ko not_active Application Discontinuation
- 2003-07-14 BR BR0313197-1A patent/BR0313197A/pt not_active IP Right Cessation
- 2003-07-14 MX MXPA05001390A patent/MXPA05001390A/es active IP Right Grant
- 2003-07-14 JP JP2004526000A patent/JP2005539009A/ja active Pending
- 2003-07-14 WO PCT/US2003/019558 patent/WO2004013093A2/en active Application Filing
- 2003-07-14 CA CA002494074A patent/CA2494074A1/en not_active Abandoned
-
2004
- 2004-08-26 US US10/926,192 patent/US7495114B2/en not_active Expired - Fee Related
- 2004-10-14 US US10/963,711 patent/US7414073B2/en not_active Expired - Fee Related
-
2005
- 2005-02-01 IL IL16662405A patent/IL166624A0/xx unknown
- 2005-03-01 NO NO20051108A patent/NO20051108L/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO20051108L (no) | 2005-05-02 |
MXPA05001390A (es) | 2005-07-29 |
US7414073B2 (en) | 2008-08-19 |
WO2004013093A2 (en) | 2004-02-12 |
KR20050032110A (ko) | 2005-04-06 |
US20050026997A1 (en) | 2005-02-03 |
JP2005539009A (ja) | 2005-12-22 |
AU2003247587B2 (en) | 2009-07-09 |
CA2494074A1 (en) | 2004-02-12 |
IL166624A0 (en) | 2006-01-15 |
US20050085513A1 (en) | 2005-04-21 |
AU2003247587A1 (en) | 2004-02-23 |
US7495114B2 (en) | 2009-02-24 |
WO2004013093A3 (en) | 2004-07-01 |
CN1684948A (zh) | 2005-10-19 |
CN100522955C (zh) | 2009-08-05 |
EP1534674A4 (en) | 2007-11-28 |
EP1534674A2 (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313197A (pt) | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico | |
ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
HK1049997A1 (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
BR0013905A (pt) | Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
BR0312464A (pt) | Inibidores de tirosina quinases | |
SG127738A1 (en) | Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds | |
DK0836380T3 (da) | FGF9 som en specifik ligand for FGFR3 | |
BRPI0515684A (pt) | formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas | |
DE69840909D1 (de) | Analoge von kokain | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
BRPI0509074A (pt) | composições farmacêuticas compreendendo agonistas do receptor da tiróide | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
BRPI0410418A (pt) | fenil quinolinas e seu uso como moduladores do receptor de estrogênio | |
BR0014320A (pt) | Composições de substâncias terapêuticas solúveis em tocol | |
BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
BR0010648A (pt) | Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril | |
BRPI0514035A (pt) | composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto | |
BRPI0516105A (pt) | composições de fator de crescimento derivado de plaqueta e métodos de uso destas | |
BR0017338A (pt) | Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão | |
PE44799A1 (es) | Antagonistas del receptor de vitronectina | |
ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
GEP20033081B (en) | Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 305/14, C07D 40712, C07D 407/14, C07D 409/12, A61K 31/337, A61K 31/337, A61P 31/04, A61P 31/12, A61P 33/00, A61P 35/00, A61P 37/06, A61P 43/00 Ipc: C07D 305/14 (2011.01) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012. |